¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"HIV Fusion Inhibitors"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • beta-lactamase inhibitors
    º£Å¸¶ô޾ÆÁ¦¾ïÁ¦Á¦
  • HIV
    »ç¶÷¸é¿ª°áÇ̹ÙÀÌ·¯½º
  • atrial fusion beat
    ½É¹æÀ¶ÇÕ¹Úµ¿
  • binocular fusion
    µÎ´«À¶ÇÕ, ¾ç¾ÈÀ¶ÇÕ
  • critical flicker fusion
    ÀÓ°èÇø®Ä¿À¶ÇÕ
  • critical fusion frequency
    ÀÓ°èÀ¶ÇÕºóµµ
  • cell fusion
    ¼¼Æ÷À¶ÇÕ
  • extraarticular fusion
    °üÀý¿Ü°íÁ¤(¼ú)
  • epiphyseal fusion
    »À³¡À¯ÇÕ(¼ú), °ñ´ÜÀ¯ÇÕ(¼ú)
  • fusion
    1. À¶ÇÕ, À¶ÇØ 2. °íÁ¤¼ú, À¯ÇÕ¼ú
  • fusion beat
    À¶ÇÕ¹Úµ¿
  • fusion defect
    À¶ÇÕ°áÇÔ
  • spinal fusion
    ôÃßÀ¯ÇÕ(¼ú)
  • sensory fusion
    °¨°¢À¶ÇÕ
  • urethrohymenal fusion
    ¿äµµÃ³³à¸·À¶ÇÕ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fusion
    1.À¶ÇÕ, À¶ÇØ, 2.°íÁ¤¼ú, À¯ÇÕ¼ú
  • HIV
    (¢¡human immunodeficiency virus) »ç¶÷¸é¿ª°áÇ̹ÙÀÌ·¯½º
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fusion angle
    À¶ÇÕ°¢
  • binocular fusion
    µÎ´«À¶ÇÕ, ¾ç¾ÈÀ¶ÇÕ
  • cell fusion
    ¼¼Æ÷À¶ÇÕ
  • critical flicker fusion
    ÀÓ°èÇø®Ä¿À¶ÇÕ
  • critical fusion frequency
    ÀÓ°èÀ¶ÇÕºóµµ
  • fusion defect
    À¶ÇÕ°áÇÔ
  • epiphyseal fusion
    »À³¡À¯ÇÕ¼ú, °ñ´ÜÀ¯ÇÕ¼ú
  • extraarticular fusion
    °üÀý¿Ü°íÁ¤¼ú
  • fusion
    À¶ÇÕ, À¶ÇØ, °íÁ¤¼ú, À¯ÇÕ¼ú
  • sensory fusion
    °¨°¢À¶ÇÕ
  • spinal fusion
    ôÃß°íÁ¤¼ú, ôÃßÀ¯ÇÕ¼ú
  • urethrohymenal fusion
    ¿äµµÃ³³à¸·À¶ÇÕ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • prostease inhibitors
    ´Ü¹éºÐÇØÈ¿¼Ò¾ïÁ¦¹°(Áú)(Ó±ÛÜÝÂú°ý£áÈåäð¤Úª(òõ)), ÇÁ·ÎÅ׿¡¿¡½º¾ïÁ¦¹°
  • Gag antigen in HIV infection
    HIV °¨¿°ÀÇ gag Ç׿ø
  • HIV => human immunodeficiency virus
    »ç¶÷¸é¿ª°áÇ̹ÙÀÌ·¯½º
  • HIV effect
    HIV È¿°ú<ÀÛ¿ë>
  • HIV infection
    HIV °¨¿°
  • HIV infection diagnosis
    HIV °¨¿°Áø´Ü
  • HIV testing
    HIV °Ë»ç
  • HIV-1
    Á¦1Çü »ç¶÷ ¸é¿ª°áÇ̹ÙÀÌ·¯½º
  • HIV-2
    Á¦2Çü »ç¶÷ ¸é¿ª°áÇ̹ÙÀÌ·¯½º
  • HIV=>human immunodeficiency virus
    ÀÎü ¸é¿ª°áÇÌ ¹ÙÀÌ·¯½º
  • Human immunodeficiency virus = HIV
    »ç¶÷¸é¿ª°áÇ̼º ¹ÙÀÌ·¯½º
  • Pannums fusion area
    ÆÄ´®À¶ÇÕ¿ª
  • abnormal fusion
    ºñÁ¤»óÀ¶ÇÕ
  • fusion
    À¶ÇÕ(ë×ùê)
  • fusion
    À¶ÇÕÁõ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • beta-lactamase inhibitors
    º£Å¸-¶ôޯı«È¿¼Ò¾ïÁ¦Á¦.
  • clotting inhibitors
    ÀÀ°í¾ïÁ¦Á¦(ëêͳåäð¤ð¥)
  • monoamine oxidase(MAO) inhibitors
  • mucociliary inhibitors
    Á¡¾×¼¶¸ð ¾ïÁ¦ÀÎÀÚ(¡­àéÙ¾ åäð¤ì×í­)
  • prostease inhibitors
    ´Ü¹éºÐÇØÈ¿¼Ò¾ïÁ¦¹°(Áú)(Ó±ÛÜÝÂú°ý£áÈåäð¤Úª(òõ)), ÇÁ·ÎÅ׿¡¿¡½º¾ïÁ¦¹°
  • hiv(human immunodeficiency virus)
    ÀÎü¸é¿ª°áÇ̹ÙÀÌ·¯½º(ìÑô÷Øóæ¹ÌÀù¹¡­)
  • human immunodeficiency virus=HIV
    Àΰ£ ¸é¿ª °áÇÌ ¹ÙÀÌ·¯½º
  • human immunodeficiency virus (HIV)
    »ç¶÷ ¸é¿ª°áÇ̹ÙÀÌ·¯½º
  • human immunodeficiency virus (HIV) infection
    »ç¶÷ ¸é¿ª°áÇ̹ÙÀÌ·¯½º °¨¿°
  • human immunodeficiency virus = HIV
    Àΰ£ ¸é¿ª°áÇÌ ¹ÙÀÌ·¯½º
  • human immunodeficiency virus(HIV)
    »ç¶÷ ¸é¿ª°áÇ̹ÙÀÌ·¯½º
  • abnormal fusion
    ºñÁ¤»óÀ¶ÇÕ
  • binocular fusion
    ¾ç¾ÈÀ¶ÇÕ(¡­ë×ùê).
  • carpal fusion
    ¼Õ¸ñ»ÀÀ¶ÇÕÁõ
  • cell fusion
    ¼¼Æ÷À¶ÇÕ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Fusion defect
    À¶ÇÕ°áÇÔ
    [¿¾ ¿ë¾î] À¶ÇÕ°áÇÔ
  • Fusion defect (Cleft palate)
    À¶ÇÕ°áÇÔ (ÀÔõÀå°¥¸²Áõ)
    [¿¾ ¿ë¾î] À¶ÇÕ°áÇÔ (ÀÔõÀå°¥¸²Áõ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • HIV
    (å²) human immunodeficiency virus
  • cell fusion
    ¼¼Æ÷À¶ÇÕ(á¬øàë×ùê)
  • fusion
    À¶ÇÕ(ë×ùê)
  • fusion gene
    À¶ÇÕ À¯ÀüÀÚ(ë×ùêë¶îîí­)
  • gene fusion
    À¯ÀüÀÚ À¶ÇÕ(ë¶îîí­ë×ùê)
  • nuclear fusion
    ÇÙÀ¶ÇÕ(ú·ë×ùê)
  • plasmid fusion
    Çö󽺹̵å À¶ÇÕ(ë×ùê)
  • replicon fusion
    ·¹Çø®ÄÜ À¶ÇÕ(ë×ùê)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fusion
    À¶ÇÕ, À¯ÇÕ, °íÁ¤¼ú
  • fusion
    À¶ÇÕ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CFF critical flicker fusion [test]; critical fusion frequency; cystic fibrosis factor; Cystic Fibrosis F...
cff critical flicker fusion; critical fusion frequency
MAOI MonoAmine Oxidase Inhibitors
HIV Human Immunodeficiency Virus
CD4 HIV helper cell count
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
HIV AN HIV associated nephropathy
HIV- HIV negative
HIV+ HIV positive
HIV Pr HIV protease
HIV- HIV sero-negative
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acute HIV infection syndrome
    ±Þ¼º ÀÎü ¸é¿ª °áÇÌ ¹ÙÀÌ·¯½º Áúȯ °¨¿° ÁõÈıº
  • HIV
    Àΰ£ ¸é¿ª ¾ïÁ¦ ¹ÙÀÌ·¯½º
    Human Immunodeficiency VirusÀÇ Áظ». ÈÄõ¼º ¸é¿ª °áÇÌÁõ
  • HIV antibody
    HIV Ç×ü
  • HIV associated periodontal disease
    HIV¿Í °ü·ÃµÈ Ä¡ÁÖ Áúȯ
  • HIV disease
    ÀÎü ¸é¿ª °áÇÌ ¹ÙÀÌ·¯½º Áúȯ
  • abnormal fusion
    ºñÁ¤»ó À¶ÇÕ
    ¹ß»ý ½Ã Á¶Á÷ÀÌ Á¤»óÀûÀ¸·Î ÇÕÃÄÁöÁö ¸øÇÏ´Â »óÅÂ. ´ëºÎºÐ Á¤Áߺο¡ °á¼ÕÀ» ³ªÅ¸³½´Ù.
  • binocular fusion
    ¾ç ¾È À¶ÇÕ
  • cell fusion
    ¼¼Æ÷ ÀÀÇÕ, ¼¼Æ÷ À¶ÇÕ
    µÎ Á¾·ù ÀÌ»óÀÇ ¼¼Æ÷¸¦ ¹ÙÀÌ·¯½º,
  • cervical fusion syndrome
    °æºÎ À¯ÇÕ ÁõÈıº
  • critical flicker fusion frequency
    ÇѰè ÇÁ¸¯Ä¿ À¶ÇÕÄ¡, ÇѰè ÇÁ¸¯Ä¿ Ä¡
  • flicker fusion test
    ÇÁ¸¯Ä¿ À¶ÇÕ °Ë»ç
  • fusion
    À¶ÇÕ, À¶ÇØ, À¯ÇÕ, À¶»ó, °íÁ¤¼ú
  • fusion teeth
    À¯ÇÕÄ¡
  • imperfect fusion
    ºÒ¿ÏÀü À¯ÇÕ
  • latent heat of fusion
    À¶ÇØ Àá¿­
    ¹°ÁúÀÌ ³ì´Â °úÁ¤¿¡¼­ ¿ÂµµÀÇ º¯È­¸¦ ¼ö¹ÝÇÏÁö ¾Ê°í Èí¼ö ¶Ç´Â ¹æÃâµÇ´Â ¿­·®.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
HIV integrase inhibitors Inhibitors of HIV integrase, an enzyme required for integration of viral DNA into cellular DNA.
(12 Dec 1998)
HIV protease inhibitors Inhibitors of HIV protease, an enzyme required for production of proteins needed for viral assembly.
(12 Dec 1998)
adrenergic uptake inhibitors Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (antidepressive agents, tricyclic) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.
(12 Dec 1998)
blood coagulation factor inhibitors Substances, usually endogenous, that act as inhibitors of blood coagulation. They may affect one or multiple enzymes throughout the process. As a group, they also inhibit enzymes involved in processes other than blood coagulation, such as those from the complement system, fibrinolytic enzyme system, blood cells, and bacteria.
(12 Dec 1998)
Bowman Birk protease inhibitors <pharmacology> Family of serine protease inhibitors found in seeds of leguminous plants and cereals.
(18 Nov 1997)
carbonic anhydrase inhibitors A class of compounds that reduces the secretion of h+ ions by the proximal kidney tubule through inhibition of carbonic anhydrase (carbonate dehydratase). Although their therapeutic use as diuretics is not frequent, they are used in clinical conditions where alkalinization of the urine is beneficial. Their most frequent application is in the reduction of intra-ocular pressure in the treatment of glaucoma.
(12 Dec 1998)
reverse transcriptase inhibitors Inhibitors of reverse transcriptase (RNA-directed DNA polymerase), an enzyme that synthesises DNA on an RNA template.
(12 Dec 1998)
growth inhibitors Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth (= plant growth regulators).
(12 Dec 1998)
phosphodiesterase inhibitors Compounds which inhibit or antagonise the biosynthesis or actions of phosphodiesterases.
(12 Dec 1998)
monoamine oxidase inhibitors A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. Although mao inhibitors are probably as effective as tricyclic antidepressants in the treatment of major depression, the complex, sometimes severe, and often unpredictable interactions between mao inhibitors and many other drugs and food-derived amines make their medical use difficult and potentially hazardous.
(12 Dec 1998)
platelet aggregation inhibitors Drugs or agents which antagonise or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
(12 Dec 1998)
cysteine proteinase inhibitors Exogenous and endogenous compounds which inhibit cysteine proteinases.
(12 Dec 1998)
protease inhibitors Compounds which inhibit or antagonise biosynthesis or actions of proteases.
(12 Dec 1998)
serine proteinase inhibitors Exogenous or endogenous compounds which inhibit serine proteinases.
(12 Dec 1998)
serotonin uptake inhibitors Compounds that specifically inhibit the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent. These agents have been used in treatment of depression, panic disorder, obsessive-compulsive behaviour, and alcoholism, as analgesics, and to treat obesity and bulimia. Many of the adrenergic uptake inhibitors also inhibit serotonin uptake; they are not included here.
(12 Dec 1998)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • HIV Fusion Inhibitors - »õâ Inhibitors of the fusion of HIV to host cells, preventing viral entry. This includes compounds that block attachment of HIV ENVELOPE PROTEIN GP120 to CD4 RECEPTORS.
    Synonyms : HIV Cell Fusion Inhibitors, Entry Inhibitors, HIV
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • HIV
    human immunodeficiency virus;»ç¶÷ ¸é¿ª°áÇÌ ¹ÙÀÌ·¯½º;AIDS ¹ÙÀÌ·¯½º
  • fusion
    ¿ëÇØ; À¶ÇØ
  • atomic fusion
    ¿øÀÚÇÙ À¶ÇÕ
  • atonic fusion
    ¿øÀÚÇÙÀ¶ÇÕ
  • cell fusion
    ¼¼Æ÷À¶ÇÕ
  • fusion
    À¶ÇØ;À¶Çع°;(Á¤´çÀÇ)ÇÕµ¿
  • fusion bomb
    ¼ö¼ÒÆøÅº
  • fusion point
    À¶Á¡;¿ëÇØÁ¡
  • fusion reaction
    ÇÙÀ¶ÇÕ ¹ÝÀÀ
  • fusion reactor
    ÇÙÀ¶ÇÕ·Î
  • nuclear fusion
    ÇÙÀ¶ÇÕ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á